Multiple Primary Cancers in Denmark 1943–80; Influence of Possible Underreporting and Suggested Risk Factors

HANS H. STORM, M.D., ELSEBETH LYNGE, Mag. Scient Soc., ANNE ØSTERLIND, M.D., AND OLE MØLLER JENSEN, M.D.

The Danish Cancer Registry, Institute of Cancer Epidemiology, under the Danish Cancer Society, Copenhagen, Denmark

Received January 22, 1986

The risk of developing a second primary cancer was studied among 171,749 men and 208,192 women who were reported to the Danish Cancer Registry between 1943 and 1980. Only those who survived at least two months were included in the analysis, and more than 1.7 million person-years of observation were accrued. Altogether, 15,084 second primary cancers developed, of which 13,231 were in organs other than the initial or adjacent site [relative risk (RR) = 1.01]. Adjustment for possible underreporting of multiple primary cancers increased the RR to 1.24, which stresses the need for detailed knowledge of registration procedures interpreting results from cancer registries. The unadjusted RR for all sites increased with time, from 0.94 during the first decade of follow-up (excluding the first year) to 1.13 among 30-year survivors, whereas the adjusted RR increased from 1.08 to 1.41. Elevated risks were observed for sites thought to have a common etiology. For example, cancers of smoking-related sites were increased in both directions following cancers of the oral cavity, respiratory tract, and urinary organs. For cancers suspected to have a hormone- or dietary fat-related association, significant reciprocal relationships were seen among cancers of the endometrium, ovary, and colon. Cancer treatment probably is an important factor in second cancer development, even when judged indirectly in the present study. For example, radiotherapy may have been responsible for an elevated risk of subsequent cancers of the thyroid, breast, colon, rectum, bladder, and connective tissue in long-term survivors. Chemotherapy may have increased the risk of subsequent leukemias. Our data further indicate that cancer patients have no general susceptibility to develop new malignant tumors, although high rates may be found for particular sites sharing common risk factors. Conversely, the occurrence of one cancer does not appear to protect against developing a new cancer.

Development of multiple primary cancers in the same individual constitutes a constant challenge to the medical profession and scientists working in cancer research. Should such events be attributed to host susceptibility, could two or more cancers be due to the same exogenous risk factor, or were the subsequent cancers induced by previous anticancer therapy?

Previous studies have shown that cancer patients are not a random sample of the general population, and Schoenberg [1] found that the site and the risk of second primary cancer development varied considerably by index site. This observation was recently confirmed in a collaborative study between the National Cancer Institute, U.S.A., the Connecticut Tumor Registry, and the Danish Cancer Registry [2,3,4]. The population-based cancer registry may provide new information for the evaluation and quantification of the risk of second primary cancer development, especially among long-term survivors. Among the latter group, risks associated with medical procedures,
e.g., radiotherapy, are most likely to be seen. In contrast, etiologic similarities between cancers of different sites, including host susceptibility, are likely to result in increased risks that are not dependent on the duration of survival after the first tumor. Reciprocal associations, i.e., in both directions between sites, would strengthen hypotheses of possible common etiology [5].

The relative risks of developing second primary cancers of specific sites have been presented in detail elsewhere, according to organ system of the first primary cancer [4,6–14]. The present paper evaluates the possible influence of underreporting and draws attention to associations indicating common etiology and to the role that treatment for the first cancer has for subsequent cancer risk.

MATERIAL AND METHODS

Cancer Registration in Denmark

Since 1943, incident cases of cancer in Denmark have been reported to the Danish Cancer Registry by hospital departments, pathology institutes, and practicing physicians. Follow-up for vital status is undertaken annually by record linkage with the National Death Registry. All tumors in the Cancer Registry are coded and classified in accordance with a modified version of the Seventh Revision of the International Classification of Diseases [15]. A conservative attitude has been taken toward accepting multiple primary cancers with similar morphologies in adjacent organs, and new tumors arising within the same organ or organ pair are generally not recorded. Examination of the development of a new independent cancer in paired organs was thus not possible. Details on the procedures of the Registry have been described elsewhere [16]. Registration is voluntary but, for practical purposes, reporting of initial cancers may be regarded as complete and valid [17,18].

The records of the Cancer Registry were by means of record linkage compared with a national patient registry (LPR) holding diagnosis for all patients discharged from hospitals in Denmark in 1977 [17]. The results of that study, as well as from a detailed study of cervix cancer patients 1943–1980 [19], were used in order to evaluate possible underreporting of multiple primary cancers.

Study of Multiple Primary Cancers 1943–80

Persons with multiple primary cancers were identified by automated record linkage performed within the Registry and the risk of multiple primary cancer development determined [4]. All non-melanoma skin cancers, precancerous lesions, and duplicate notifications of the same tumor were excluded. Patients who survived less than two months or who developed a second primary cancer within the first two months following their initial cancer diagnosis were excluded, leaving 364,857 persons with a single cancer and 15,084 persons with a second primary cancer available for study. A total of 551 third and fourth primary cancers occurred in these individuals but were not considered in this study. These 379,941 eligible patients, 171,749 men and 208,192 women, were on average followed for five years and accumulated 1,706,736 person-years of observation. Second primary cancers developed in 4.2 percent of the women and 3.7 percent of the men. In persons with multiple tumors, approximately 92 percent of the first and 85 percent of the second primary cancers were verified histologically. Only 4 percent of the second primary cancers were known to the Registry solely from death certificates.
Calculation of Relative Risks

Person-years at risk were calculated from the date of diagnosis of the first primary cancer (i.e., date of first hospital admission) until the date of diagnosis of a second primary cancer, death, or December 31, 1980, whichever occurred first. The expected numbers of second cancers were estimated by applying sex and site-specific incidence rates for the general population in Denmark to the corresponding person-years of observation, using a modified version of the program developed by Monson [20]. The relative risk (RR) was taken as the ratio of observed to expected incident cancers and approximate 95 percent confidence intervals (CI) of the RR were computed, assuming a Poisson distribution of the observed cancers as described by Rothman and Boice [21].

RESULTS AND DISCUSSION

All Cancers

For both sexes combined, 16,580 second primary cancers were expected, yielding a deficit of approximately 1,500 cancers (RR = 0.91; 95 percent CI = 0.90–0.92), as shown in Table 1. The risk of second primary cancer increased significantly with the time, since diagnosis of the first primary (p < .001 for trend), from RR = 0.9 in short-term survivors to RR = 1.1 among those living 30 or more years after their initial primary cancer (Table 2). The present finding corresponds to an annual average incidence of 8.8 second cancers per 1,000 persons (7.8/1,000 women; 10.9/1,000 men). These findings agree well with other results [22,23,24]; however, a significant 31 percent increased RR of second cancer in Connecticut [3] was not matched by a similar increase in our investigation. Differences in registration procedures may explain some of the discrepant results between Denmark and Connecticut.

The overall deficit of cancers occurred mainly during the first five years of follow-up [4]. During this early follow-up period, both the notifying physician and the Registry would be hesitant to accept and record a new primary cancer, as a large proportion of such tumors would likely be regarded as misdiagnosed metastases. In Connecticut, no similar deficit was observed [3]; in fact the 30 percent excess is present throughout all time intervals since first primary diagnosis. If the observed and expected second

| Adjustment | (O) | (E) | (O/E) |
|------------|-----|-----|-------|
| None       | 16,727 | 15,084 | 18,523 |
| E          | 12,797 | 16,580 | 16,580 |
| O/E        | 1.31 | 0.91 | 1.12 |

Excluding site of initial cancer

| Adjustment | (O) | (E) | (O/E) |
|------------|-----|-----|-------|
| O          | 12,831 | 13,231 | 16,247 |
| E          | 10,428 | 13,113 | 13,113 |
| O/E        | 1.23 | 1.01 | 1.24 |

*From [3]
*From [4]
'Adjusted for possible underreporting
cancers of the same site as the index cancer were subtracted, and when excluding cancers of buccal cavity following a cancer of lip, tongue, and mouth; colorectal cancers after a colorectal; female genital after an initial female genital; urinary following another urinary; and a hematological malignancy following a primary hematological cancer [3], the RR increased to 1.01 in Denmark and was not significantly different from unity, while the RR in Connecticut decreased from 1.31 to 1.23 (Table 1).

The change of the RR in opposite directions in Connecticut and Denmark indicates different attitudes to recording of multiple tumors by these two cancer registries, overreporting of multiple primary cancers may thus take place in Connecticut, in contrast to Denmark, where underreporting may be equally important. It has been possible to evaluate reporting of multiple cancers in Denmark. A similar evaluation of other Registry data, including Connecticut’s, has to our knowledge not been undertaken.

Table 3 shows the results of a linkage study among cancer patients known both to the Cancer Registry and to the LPR [17]. According to the LPR, 6.8 percent of the cancer patients admitted to hospitals in 1977 had multiple primary cancers, whereas the Cancer Registry 1943–80 observed 4.0 percent. However, it is important to emphasize that the LPR is not a cancer registry. This registry holds all discharge diagnoses (20 possible) for every single hospital admission linked to the personal identifying number provided all Danish inhabitants. If a patient had more hospital admissions, no attempt was made to link the discharge information from the various admissions and thus to avoid duplications and errors if a diagnosis was revised. Consequently the LPR had to be edited to simulate a Cancer Registry, and the computerized editing process may have allowed for too many multiple cases [17]. For example, a patient with a cancer in

### Table 2
Relative Risk of Second Primary Cancer Following Any Primary Cancer in Denmark, 1943–1980

| Year Since First Primary | Uncorrected | Corrected |
|-------------------------|-------------|-----------|
|                         | O  | E   | RR | O  | E   | RR |
| 1–9                     | 8,399 | 8,979.6 | 0.94 | 9,710 | 8,979.6 | 1.08 |
| 10–19                   | 3,458 | 3,504.0 | 0.99 | 4,257 | 3,504.0 | 1.22 |
| 20–29                   | 1,158 | 1,187.3 | 0.98 | 1,470 | 1,187.3 | 1.24 |
| 30+                     | 190  | 167.6 | 1.13 | 236  | 167.6 | 1.41 |

*Number corrected for estimated degree of underreporting

### Table 3
Frequency of Multiple Primary Cancers in Denmark Estimated from the Danish Cancer Registry 1943–80 (CRG), National Patient Discharge Registry 1977 (LPR), and Cervix Cancer Cohort 1943–82 (CCC)

| Cancer Case | CRG     | (%) | LPR   | (%) | CCC    | (%) |
|-------------|---------|-----|-------|-----|--------|-----|
| Single      | 364,857 | (96.0) | 15,342 | (93.2) | 22,779 | (91.2) |
| Multiple    | 15,084  | (4.0) | 1,126  | (6.8) | 2,191* | (8.8) |

*Estimated, based on scrutiny of 7.5 percent sample of all notified single cervix cancer cases and 35 percent sample of all notified second primaries after cervix cancer
the sigmoid colon, with a primary discharge diagnosis of colon cancer, may, at a later admission, have been discharged as a rectal cancer case and thus calculated as a multiple primary case. If the patient later was admitted with lung metastasis, and the discharge diagnosis in error stated lung cancer, this too would give rise to a multiple primary case. The validity of the cancer discharge diagnoses in the LPR is currently under evaluation.

On the other hand, some second primary cancers are not reported to the Registry, as was demonstrated in a study of second primary cancer within a cohort of 24,970 cervix cancer patients [19]. Diagnostic information on 627 cases with a known second primary cancer and 1,705 matched controls, with no knowledge of any other cancer but the cervix cancer, were evaluated by thorough scrutiny of all hospital and pathology records available from the date of cervix cancer diagnosis until death or December 1982. Based on these results, 8.8 percent of all cancer patients should have a second primary cancer, which is more than twice as many as reported to the Registry (Table 3).

In order to evaluate the upper limit of possible underreporting, we applied these results from the cervix cancer study on the Cancer Registry cohort of single cancer cases, taking account of time elapsed between the first and second primary cancer (Table 4). No account of the influence of overreporting of multiple primary cancers was taken, as the influence would be minor. The largest proportion (7.2 percent of total 18.6 percent) of unreported second primaries (1,337) was observed within the first five years of observation (the mean observation time of the Cancer Registry cohort). The total estimated number of unreported second primaries would be 3,439 cases, which would increase the number of second primary cancers from 15,084 to 18,523. When applying these corrected observed numbers, the overall RR changes from 1.01 to 1.24, which is similar to the observed RR (1.23) in Connecticut (Table 1), while the RR by time since first primary increases from 1.1 to 1.4, 30 years or more after the first cancer (Table 2).

| Time Elapsed Since First Tumor (years) | 0–4 | 5–9 | 10–19 | 20–29 | 30+ | Total |
|---------------------------------------|-----|-----|-------|-------|-----|-------|
| CCC “Single”                          |     |     |       |       |     |       |
| No. starting interval                 | 1,705 | 1,629 | 1,405 | 802   | 237 | 1,705 |
| Unreported second primary             | 6    | 6    | 26    | 19    | 4   | 65    |
| % unreported                          | 0.4  | 0.6  | 1.9   | 2.4   | 1.7 | 3.8   |
| Cancer Registry                       |     |     |       |       |     |       |
| No. single cases starting interval    | 379,941 | 102,664 | 56,430 | 18,121 | 3,699 | 379,941 |
| Reported second primary               | 6,831 | 3,447 | 3,458 | 1,158 | 190 | 15,084 |
| Unreported second primary             | 1,337 | 567  | 1,044 | 429   | 62  | 3,439 |
| Estimate no. second primary           | 8,168 | 4,014 | 4,502 | 1,587 | 252 | 18,523 |
| Underreporting of Second Primary      |     |     |       |       |     |       |
| % in interval                         | 16.4 | 14.1 | 23.2  | 27.0  | 24.6| 18.6  |
| % of total                            | 7.2  | 3.1  | 5.6   | 2.3   | 0.3 | 18.6  |
It must be borne in mind that these figures represent the upper limit of underreporting. Furthermore, it is unknown whether they are applicable to the entire Registry material, as they were derived from underreporting observed in following only one site, cervix. Differences in registration procedures [16,25] and probably definitions of second primary cancers between the registries in Denmark and Connecticut thus are an important factor in evaluation of discrepant results. In view of the underreporting of multiple cancer, the significant elevated RRs of second primary cancers in Denmark may be regarded as minimum figures, whereas an insignificant elevated RR or decreased RR is difficult to interpret.

RELATIONSHIPS BETWEEN SITES OF FIRST AND SECOND PRIMARY CANCERS

The overall risk of a new primary cancer among all cancer patients is composed of excesses and deficits of various second tumors after different first primary cancers [6-14]. Thus the constellation of multiple tumors that occurs in individuals with the same first primary cancer may provide clues to factors that influence risk.

When bidirectional associations appear to be independent of intervals between

| First Primary | Second Primary | O/E | 95% CI   |
|---------------|---------------|-----|---------|
| Lip           | Mouth         | 2.4 | 1.1-4.8 |
|               | Larynx        | 0.1 | 0.0-0.6 |
| Tongue        | Mouth         | 12.0| 2.4-35.0|
|               | Lung          | 2.5 | 1.4-4.1 |
| Mouth         | Lip           | 6.3 | 2.5-12.9|
|               | Tongue        | 20.8| 6.7-48.6|
|               | Esophagus     | 5.3 | 2.3-10.5|
|               | Lung          | 2.4 | 1.6-3.4 |
| Pharynx       | Larynx        | 5.1 | 1.0-14.9|
|               | Lung          | 1.9 | 1.1-3.2 |
| Larynx        | Lung          | 2.6 | 2.2-3.1 |
|               | Pancreas      | 1.7 | 1.0-2.6 |
| Lung          | Larynx        | 3.1 | 2.0-4.7 |
|               | Kidney        | 2.7 | 2.0-3.6 |
|               | Bladder       | 1.6 | 1.2-2.0 |
| Kidney        | Bladder       | 7.1 | 6.0-8.4 |
| Bladder       | Lung          | 1.6 | 1.4-1.8 |
|               | Kidney        | 3.2 | 2.7-3.8 |
| Pancreas      | Kidney        | 2.7 | 1.1-5.6 |
| Cervix        | Esophagus     | 2.0 | 1.2-3.0 |
|               | Lung          | 2.8 | 2.4-3.2 |
|               | Kidney        | 1.4 | 1.1-1.8 |
|               | Bladder       | 3.0 | 2.5-3.5 |
tumor diagnosis, common etiologic factors are suspected. Tobacco smoking appears to underlie the associations between cancers of the oral cavity and pharynx, esophagus, respiratory system, urinary tract, pancreas, and cervix [26–31] (Table 5). Not only do smokers have an increased risk of developing cancer of these sites, but persons who develop one of these cancers have an increased risk of yet another smoking-related tumor [4,6,7,8,10,12]. One-third of all 481 second tumors seen in lung cancer patients could be considered to be related to smoking, which explains the 20 percent excess of second primary cancer among lung cancer patients [6].

For cancers of the oral cavity and pharynx, the elevated RR of cancer of adjacent sites can be attributed to tobacco (and alcohol), and the same applies to the reciprocal associations between kidney and bladder cancer. However, it is difficult for us to rule out the influence of misdiagnosis and misclassification of metastatic spread on the risk estimates for tumors arising from the same organ system, and host factors may play an important role in promoting multifocal tumors and predisposing to the influence of environmental risk factors. The associations between tobacco-related sites and cancer of the cervix may be confounded by socioeconomic and other characteristics associated both with smoking and cervical cancer [32].

Nutritional and hormonal factors probably affect the reciprocal associations observed between cancers of the large bowel, breast, and female genital organs (Table 6). Although the associations are weak and misdiagnosis of metastatic spread in the abdominal cavity could bias results, cancers of the colon, rectum, biliary tract, pancreas, breast, endometrium, ovary, and prostate may have similar dietary and nutritional determinants, such as fat intake [33]. However, the biologic mechanisms involved are not clear, and the suggested relationship with fat for many of these sites is based mainly on evidence from international correlations [34]. Some of these cancers evolve in hormone-dependent organs, particularly cancers of the breast, corpus uteri, and ovary, and it has been suggested that the risk for females developing colon cancer may also be related to endocrine factors [35]. Thus, an association in both directions between cancer of the colon and cancers of the endometrium and ovary is interesting. The overall absence of strong bidirectional associations between cancers of these sites may be due to a weak association with fat [1,22,23], little variation in the diet of the Danish population, or a possible underreporting of multiple primary cancers.

Obesity has been associated with cancers of the endometrium and breast [29], possibly due to the increased production of endogenous estrogens [36]. Several studies show an association between the use of estrogen unopposed by progesterone and

| First Primary | Second Primary | RR  | 95% CI | First Primary | Second Primary | RR  | 95% CI |
|---------------|----------------|-----|--------|---------------|----------------|-----|--------|
| Breast        | Colon          | 1.1 | 1.0–1.2| Colon         | Breast         | 0.9 | 0.8–1.1|
| Colon         | Corpus uteri   | 1.8 | 1.3–2.3| Corpus uteri  | Colon          | 1.5 | 1.3–1.7|
| Colon         | Ovary          | 2.6 | 2.1–3.1| Ovary         | Colon          | 1.7 | 1.3–2.2|
| Corpus uteri  | Breast         | 1.2 | 1.1–1.4| Breast        | Corpus uteri   | 1.0 | 0.9–1.2|
| Ovary         | Breast         | 1.1 | 0.9–1.3| Breast        | Ovary          | 1.3 | 1.1–1.4|
| Corpus uteri  | Ovary          | 0.8*| 0.6–1.0| Ovary         | Corpus uteri   | 2.3 | 1.7–3.0|

*The RR = 2.7 when allowing for hysterectomies (and thus possible oophorectomies) in calculation of risk.
endometrial cancer [37]. Some evidence indicates that estrogens may cause breast tumors, particularly in high-risk individuals [38]. Ovarian cancer has also been linked to estrogens [39]. In our study, we observed excesses of breast cancer following endometrial cancer, and an increased risk of ovarian cancer following endometrial cancer (Table 6). These data are consistent with the hypothesis that hormonal factors, including endogenous estrogens, may influence tumor development for these cancer sites.

Ionizing radiation [40] and certain chemotherapeutic drugs [41] used in the treatment of cancer are known carcinogens. To evaluate the possible influence of irradiation on second cancer development, we classified index cancer sites as irradiated if 50 percent or more received radiation, and not irradiated if 10 percent or less were irradiated (Table 7). Significant risks of solid tumors ten years or more after the initial cancer diagnosis and the risk of subsequent ANLL during the one- to nine-year follow-up interval are presented, as radiogenic leukemias are known to appear early, contrary to solid tumors.

A 2.7-fold and a 1.6-fold increased risk of thyroid and breast cancers, respectively, was observed following head and neck cancer. The thyroid gland is known to be

| First Primary Site, % Irradiated | Second Primary Cancer | Irradiated a | Not Irradiated b |
|---------------------------------|-----------------------|--------------|-----------------|
|                                 | RR        | 95% CI       | RR       | 95% CI       |
| Head and neck, 76%              | Thyroid   | 2.7          | 1.0–6.0  | 0.8          | 0.1–2.8 |
|                                 | Female breast | 1.6          | 1.0–2.2  | 1.0          | 0.8–1.4 |
|                                 | ANLL      | 1.1          | 0.4–2.5  | 1.1          | 0.6–1.8 |
| Genital organs, 65%             | Colon     | 1.2          | 1.0–1.4  | 1.0          | 0.8–1.3 |
|                                 | Rectum    | 1.5          | 1.2–1.8  | 1.4          | 1.1–1.9 |
|                                 | Bladder c | 2.6          | 2.2–3.2  | 0.8          | 0.5–1.2 |
|                                 | Connective tissue | 2.5          | 1.2–4.6  | 0.7          | 0.0–3.8 |
|                                 | ANLL      | 1.9          | 1.1–3.1  | 1.1          | 0.6–1.8 |
| Female breast, 69%              | Salivary gland | 3.2          | 1.3–6.5  | 0.8          | 0.0–4.7 |
|                                 | Esophagus | 1.7          | 1.0–2.9  | 1.0          | 0.4–2.1 |
|                                 | Lung      | 1.7          | 1.3–2.1  | 1.0          | 0.7–1.3 |
|                                 | Ovary     | 1.5          | 1.2–1.9  | 0.5          | 0.2–1.1 |
|                                 | Connective tissue | 4.2          | 2.1–7.6  | 0.7          | 0.0–3.8 |
|                                 | ANLL      | 2.7          | 1.9–3.9  | 1.1          | 0.6–1.8 |
| Hodgkin's and NHL 64%           | Lung      | 1.8          | 1.0–2.9  | 1.0          | 0.7–1.3 |
|                                 | Female breast | 2.1          | 1.1–3.5  | 1.0          | 0.8–1.4 |
|                                 | Bladder   | 2.6          | 1.3–4.7  | 0.8          | 0.5–1.2 |
|                                 | ANLL      | 8.4          | 4.0–15.5 | 1.1          | 0.6–1.8 |

a50 percent or more initial cancers irradiated
b10 percent or less (average 4 percent) received irradiation (primary sites: stomach, small intestine, colon, liver, gallbladder, and pancreas).
cIncludes cancers of the lip, tongue, salivary glands, gum, mouth, pharynx, larynx, and nasal cavities
dIncludes cancers of testis, cervix, and corpus uteri
'Includes bladder papillomas
sensitive to radiation, and increased cancer risks have previously been described following X-rays to the head and neck region [42], treatment for tinea capitis [43], and among atomic bomb survivors [44]. The breast cancer excess is unlikely to be attributable to radiation of the head and neck region because in most instances the breast would not be in or near the therapeutic fields. The same argument would apply to head and neck cancers following breast irradiation. A bidirectional association between salivary gland tumors and breast cancer has been described [45,46], but this was only suggested among long-term survivors in our study [6,9]. However, the elevated risk of salivary gland tumors following a breast cancer indicates that these sites share some common etiology.

The relative risks of cancers of the colon (1.2), rectum (1.5), bladder (2.6), and connective tissue (2.5) following a frequently irradiated genital cancer were not unexpected, as all these organs are close to the radiation fields used to treat genital cancers [47]. The RRs for colon and rectal cancer are compatible with those seen for other irradiated populations, e.g., patients with ankylosing spondylitis and metropathia hemorrhagica [48,49]. However, common risk factors for genital and gastrointestinal cancers or misdiagnosed metastases may account for some of the increased risks.

The increased risks of cancers of the esophagus and lung following breast cancer are consistent with a radiation effect which has been seen in studies of atomic bomb survivors [50]. It is unlikely that the increased risk of ovarian cancer following breast cancer is related to castration radiotherapy because only 6 percent of Danish breast cancer patients received such treatment [51].

Solid tumors were also in excess among long-term survivors with malignant lymphoma, in particular cancers of the lung, female breast, and bladder (Table 7). Radiation may have increased the risk of second cancers in some instances, such as following the inverted Y irradiation for Hodgkin's disease that exposes a large proportion of the body trunk. Common etiologies and misdiagnoses of lymphatic infiltrations could also be involved.

Significantly increased RR of ANLL was noted during the first ten years of follow-up among patients with initial cancers of the genital organs (1.9), female breast cancer (2.7), and malignant lymphoma (8.4) (Hodgkin's disease, 20.6; NHL, 3.5). Interestingly, the RR of ANLL remained significantly elevated among long-term survivors of breast cancer (2.3) [9] and malignant lymphoma (Hodgkin's disease, 14.3; NHL, 7.1) [14].

The induction of acute leukemia, especially ANLL, is a well-known consequence of radiation [52–54]. The pattern of increased risk of ANLL within the first ten years after exposure is consistent with previous reports [55] and different from that observed for solid tumors. The late excesses of ANLL ten years or more after initial diagnosis may be related to treatment of recurrent disease. For Hodgkin's disease and NHL, chemotherapy undoubtedly contributed to the increased risk of leukemia as reported by others [52,56–58]. Our present findings do not allow us to state whether radiation, chemotherapy, or both are associated with ANLL, but previous studies have indicated that alkylating agents are much more likely to be responsible for the increased leukemia risk than is radiotherapy [59].

CONCLUSION

Many factors influence the results from our study on multiple primary cancers in Denmark. Utilization of Cancer Registry data is subject to differences in reporting and
coding practices during the years of operation. Medical surveillance, specificity of diagnostic methods, and local interest as well as changes in risk factors may over the years modify the risk. Nonetheless, the usefulness of a population-based cancer registry in a well-defined population for evaluation and quantification of the risk of second primary cancers is demonstrated. The long period of follow-up allows consideration of time trends even for rare cancers.

Even if the overall risk of a person developing a second cancer at a different site from the first may be slightly underestimated, this study shows that a RR above 1.3 may be ruled out when possible underreporting is taken into account. Our results suggest that cancer patients overall are not at high risk of developing new malignant tumors. Conversely, the occurrence of one cancer does not appear to protect against the development of a new tumor in another organ.

Elevated rates may occur for particular combinations of sites, especially those related to common risk factors. No specific risk factor could be examined in the present descriptive study, but several etiologic leads have been suggested or confirmed, i.e., cigarette smoking, hormonal and nutritional factors, radiation, and chemotherapy.

Studies of multiple primary neoplasms provide researchers with a strategy to investigate the exogenous and endogenous determinants of cancer. To increase the value of the survey data, staffs of population-based cancer registries must give attention to improvements in registration of multiple cancers in the same individual and agree to rules that facilitate international comparisons. This is important with a view to future etiologic studies and to the identification of high-risk cancer patients who should be monitored closely for the early detection and management of second primary cancers.

ACKNOWLEDGEMENT

The authors wish to thank Mr. N. Christensen, Danish Cancer Registry, for assisting with all computations for this investigation. Ms. M. Harnek and Ms. Helle N. Nielsen helped with the preparation of the manuscript.

This work was supported by a special grant from the Danish Cancer Society (84-066), under whose auspices the Danish Cancer Registry operates.

REFERENCES

1. Schoenberg BC: Multiple primary malignant neoplasms: The Connecticut experience, 1935–1964. Berlin, New York, Springer Verlag, 1977
2. Boice JD Jr, Storm HH, Curtis RE, et al: Introduction to the study of Multiple Primary Cancers. Natl Cancer Inst Monogr 68:3–9, 1985
3. Curtis RE, Boice JD Jr, Kleinerman RA, Flannery JT, Fraumeni JF Jr: Multiple Primary Cancers in Connecticut, 1935–82. Natl Cancer Inst Monogr 68:219–242, 1985
4. Storm HH, Jensen OM, Ewertz M, Lynge E, Olsen JH, Schou G, Østerlind A: Multiple Primary Cancers in Denmark, 1943–80. Natl Cancer Inst Monogr 68:411–430, 1985
5. Schottenfeld D: Multiple primary cancers. In Cancer Epidemiology and Prevention. Edited by D Schottenfeld, JF Fraumeni Jr. Philadelphia, Saunders, 1982, pp 1025–1035
6. Schou G, Storm HH, Jensen OM: Second cancer following cancer of the buccal cavity and pharynx in Denmark, 1943–80. Natl Cancer Inst Monogr 68:253–276, 1985
7. Lynge E, Jensen OM, Carstensen B: Second cancer following cancer of the digestive system in Denmark, 1943–80. Natl Cancer Inst Monogr 68:277–308, 1985
8. Olsen JH: Second cancer following cancer of the respiratory system in Denmark, 1943–80. Natl Cancer Inst Monogr 68:309–324, 1985
9. Ewertz M, Mouridsen HT: Second cancer following cancer of the female breast in Denmark, 1943–80. Natl Cancer Inst Monogr 68:325–329, 1985
10. Storm HH, Ewertz M: Second cancer following cancer of the female genital system in Denmark, 1943–80. Natl Cancer Inst Monogr 68:331–340, 1985
11. Østerlind A, Rørth M, Prener A: Second cancer following cancer of the male genital system in Denmark, 1943–80. Natl Cancer Inst Monogr 68:341–347, 1985
12. Jensen OM, Knudsen JB, Sørensen LB: Second cancer following cancers of the urinary system in Denmark, 1943–80. Natl Cancer Inst Monogr 68:349–360, 1985
13. Østerlind A, Olsen JH, Lyne E, Ewertz M: Second cancer following cutaneous melanoma and cancers of the brain, thyroid, connective tissue, bone, and eye in Denmark, 1943–80. Natl Cancer Inst Monogr 68:361–388, 1985
14. Storm HH, Prener A: Second cancer following lymphatic and hematopoietic cancers in Denmark, 1943–80. Natl Cancer Inst Monogr 68:389–411, 1985
15. Danish Cancer Registry: Cancer incidence in Denmark 1978, 1979 and 1980. Copenhagen, Danish Cancer Society, 1983
16. Jensen OM, Storm HH, Jensen HS: Cancer registration in Denmark and the study of multiple primary cancers, 1943–80. Natl Cancer Inst Monogr 68:245–251, 1985
17. Østerlind A, Jensen OM: Evaluation of registration of cancer cases in Denmark in 1977. Preliminary evaluation of registration of cancer cases by the Cancer Registry and the National Patient Registry. Ugeskr Laeger 147:2483–2488, 1985
18. Storm HH: Validity of Death Certificates for Cancer Patients in Denmark 1977. Copenhagen, Danish Cancer Registry, Danish Cancer Society, 1984
19. Storm HH, Boice JD Jr: Leukemia after cervical cancer irradiation in Denmark. Int J Epid 14:363–368, 1985
20. Monson RR: Analysis of relative survival and proportional mortality. Comput Biomed Res 7:325–332, 1974
21. Rothman KJ, Boice JD Jr: Epidemilogic analysis with a Boston, programmable calculator. Boston, Epidemiology Resources Inc, 1982, pp 30–31
22. Schottenfeld D, Berg JW: Epidemiology of multiple primary cancers. In Cancer Epidemiology and Prevention: Current Concepts. Edited by D Schottenfeld. Springfield, IL, Charles C Thomas, 1975, pp 416–434
23. Mortel CG, Dockerty MB, Baggenstos AH: Multiple primary malignant neoplasms. I. Introduction and presentation of data. II. Tumors of different tissues or organs. Cancer 14:221–237, 1961
24. Teppo L, Pukkala E, Saxen E: Multiple cancer—an epidemiologic exercise in Finland. JNCI 75:207–217, 1985
25. Flannery JT, Boice JD Jr, Devesa SS, Kleinermann RE, Curtis RE, Fraumeni JF Jr: Cancer registration in Connecticut and the study of multiple primary cancers, 1935–82. Natl Cancer Inst Monogr 68:13–24, 1985
26. Office on Smoking and Health, Office of the Assistant Secretary for Health: Smoking and Health, a Report of the Surgeon General. DHEW Publ No (PHS)79-50066. Washington, DC, U.S. Government Printing Office, 1979, pp 5.1–5.74
27. Wynder EL: An epidemiologic evaluation of the causes of cancer of the pancreas. Cancer Res 35:2228–2233, 1975
28. Trichopoulos D, MacMahon B, Sparros L, Merikas G: Smoking and hepatitis B-negative primary hepatocellular carcinoma. JNCI 65:111–114, 1980
29. McLaughlin JK, Mandel JS, Blot WJ, Schuman LM, Mehl ES, Fraumeni JF Jr: A population based case-control study of renal cell carcinoma. JNCI 72:275–284, 1984
30. Kelsey JL, Hildreth NG: Breast and gynecologic cancer epidemiology. Boca Raton, FL, CRC Press, 1983
31. Brinton LA, Blot WJ, Becker JA, Winn DM, Browder JD, Farmer JC Jr, Fraumeni JF Jr.: A case-control study of cancers of the nasal cavity and paranasal sinuses. Am J Epidemiol 119:896–906, 1984
32. Olsen JH, Borch-Johnsen K, Roed-Pedersen B: Smoking habits and occupational employment. Ugeskr Laeg 147:2788–2792, 1985
33. Wynder EL, McCoy GD, Reddy BS, Cohen L, Hill P, Spingarn NE, Weisburger JH: Nutrition and metabolic epidemiology of cancers of the oral cavity, esophagus, colon, breast, prostate and stomach. In Nutrition and Cancer. Edited by GR Newell, NM Ellison. New York, Raven Press, 1981, pp 11–48
34. Doll R, Peto R: The causes of cancer: Quantitative estimates of avoidable risks of cancer in the United States today. JNCI 66:1191–1308, 1981
35. McMichael AJ, Potter JD: Reproduction, endogenous and exogenous sex hormones and colon cancer: A review and hypothesis. JNCI 65:1201–1207, 1980
36. Siiteri PK, Hemsell DL, Edwards CL, MacDonald PC: Estrogen and endometrial carcinoma. In Endocrinology: Proceedings of the Fourth International Congress of Endocrinology. Edited by R Scow. Amsterdam, Excerpta Medica, 1973, pp 1237–1242
37. Gusberg SB: Current concepts in cancer. The changing nature of endometrial cancer. New Eng J Med 302:729–731, 1980
38. Bibbo M, Haenzel WM, Wied GL, Hubby M, Herbst AL: A twenty-five year follow-up study of women exposed to diethylstilbestrol during pregnancy. New Eng J Med 298:763–767, 1978
39. Hoover R, Gray LA, Fraumeni JF Jr: Stilbestrol (diethylstilbestrol) and the risk of ovarian cancer. Lancet ii:533–534, 1977
40. Jablon S: Epidemiologic perspectives in radiation carcinogenesis. In Radiation Carcinogenesis: Epidemiology and Biological Significance. Edited by JD Boice Jr, JF Fraumeni Jr. New York, Raven Press, 1984, pp 1–8
41. International Agency for Research on Cancer working group on the evaluation of carcinogenic risk of chemicals to humans: Some anticancer and immunosuppressive drugs. IARC Sci Publ No. 26. Lyon, France, IARC, 1981
42. Shore RE, Woodward ED, Hempelmann LH: Radiation-induced thyroid cancer. In Radiation Carcinogenesis: Epidemiologic and Biological Significance. Edited by JD Boice Jr, JF Fraumeni Jr. New York, Raven Press, 1984, pp 131–138
43. Ron E, Modan B: Thyroid and other neoplasms following childhood scalp irradiation. In Radiation Carcinogenesis: Epidemiology and Biological Significance. Edited by JD Boice Jr, JF Fraumeni Jr. New York, Raven Press, 1984, pp 139–151
44. Prentice RL, Kato H, Yoshimoto K, Mason M: Radiation exposure and thyroid cancer incidence among Hiroshima and Nagasaki residents. Natl Cancer Inst Monogr 62:207–212, 1982
45. Berg JW, Hutter RV, Foote FW Jr: The unique association between salivary gland cancer and breast cancer. JAMA 204:771–774, 1968
46. Prior P, Waterhouse JA: Second primary cancer in patients with tumors of the salivary glands. Br J Cancer 36:362–367, 1977
47. Stovall M: Organ doses from radiotherapy of cancer of the uterine cervix. In Second Cancer in Relation to Radiation Treatment for Cervical Cancer. Edited by NE Day, JD Boice Jr. IARC Sci Publ No. 52. Lyon, France, IARC, 1983, pp 131–136
48. Court Brown WM, Doll R: Mortality from cancer and other causes after radiotherapy for ankylosing spondylitis. Br Med J 2:1327–1332, 1965
49. Smith PG, Doll R: Late effects of x irradiation in patients treated for metropathia haemorrhagica. Br J Radiol 49:224–232, 1976
50. Beebe GW, Kato H, Land CE: Studies of the mortality of A-bomb survivors. 6. Mortality and radiation dose, 1950–74. Radiat Res 75:138–210, 1978
51. Ewertz M, Machado GS, Boice JD Jr, Jensen OM: Endometrial cancer following treatment for breast cancer: A case-control study in Denmark. Br J Cancer 50:687–692, 1984
52. Green MH, Young RC, Merrill JM, Vincent TS: Evidence of a treatment dose response in non-lymphocytic leukemias which occur after therapy of non-Hodgkin’s lymphoma. Cancer Res 43:1891–1898, 1983
53. Ichimaru M, Ishimaru T, Belsky JL: Incidence of leukemia in atomic bomb survivors belonging to a fixed cohort in Hiroshima and Nagasaki, 1950–71. Radiation dose, years after exposure, age at exposure, and type of leukemia. Jpn Radiat Res 19:262–282, 1978
54. Wagoner JK: Leukemia and other malignancies following radiation therapy for gynecological disorders. In Radiation Carcinogenesis: Epidemiology and Biological Significance. Edited by JD Boice Jr, JF Fraumeni Jr. New York, Raven Press, 1984, pp 153–159
55. National Academy of Sciences: The effects on populations to exposure to low levels of ionizing radiation: 1980. Washington, DC, National Academy Press, 1980
56. Pedersen-Bjergaard J, Philip P, Pedersen NT, Hou-Jensen K, Sveggaard A, Jensen G, Nissen N: Acute non-lymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome secondary to treatment of other malignant diseases. II. Bone marrow cytology, cytogenetics, results of HLA typing, response to antileukemic chemotherapy, and survival in a total series of 55 patients. Cancer 54:452–462, 1984
57. Curtis RE, Hankey BF, Myers MH, Young JL Jr: Risk of leukemia associated with the first course of
cancer treatment: An analysis of the surveillance, epidemiologic and end results program experience. JNCI 72:531–544, 1984

58. Pedersen-Bjergård J, Larsen SO: Incidence of acute non-lymphocytic leukemia, preleukemia and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin’s disease. New Eng J Med 307:965–971, 1982

59. Green MH: Interaction between radiotherapy and chemotherapy in human leukemogenesis. In Radiation Carcinogenesis: Epidemiologic and Biologic Significance. Edited by JD Boice Jr, JF Fraumeni Jr. New York, Raven Press, 1984, pp 199–210